Literature DB >> 29274807

Deintensification of hypoglycaemic medications-use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes.

A H Abdelhafiz1, A J Sinclair2.   

Abstract

IMPORTANCE: Intensive treatment of older people with diabetes is common placing them at increased risk of adverse events such as hypoglycaemia and hospitalisation for drug errors. Little is known about when, how or for whom to deintensify hypoglycaemic medications.
OBJECTIVE: To explore the characteristics of patients for whom deintensification is appropriate and to determine the outcome of deintensification. EVIDENCE REVIEW: Medline, Google scholar and EmBase search from 1997 to present was performed using keywords relating to diabetes mellitus, polypharmacy, hypoglycaemia, hospitalisation, deintensification, deprescribing and reduction, simplification or withdrawal of hypoglycaemic medications. Only English language articles were selected. Articles were reviewed for relevance by abstract. A manual review of citations in retrieved articles was performed in addition to the electronic literature search.
FINDINGS: Those who are over treated appear to be of older age group, frail with weight loss and have multiple medical morbidities especially renal impairment and dementia. Simplification, reduction or even complete withdrawal of hypoglycaemic medications in these patients appears to be feasible without deterioration of glycaemic control.
CONCLUSIONS: Over treatment is common in frail older people with multiple comorbidities and deintensification appears safe in this group of patients. Current recommendations emphasise preventing underuse rather than overuse of medications, and therefore, a change in guidelines advice may be warranted.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Deintensification; Diabetes mellitus; Medications; Older people; Outcome

Mesh:

Substances:

Year:  2017        PMID: 29274807     DOI: 10.1016/j.jdiacomp.2017.11.011

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  7 in total

1.  13. Older Adults: Standards of Medical Care in Diabetes-2022.

Authors:  Boris Draznin; Vanita R Aroda; George Bakris; Gretchen Benson; Florence M Brown; RaShaye Freeman; Jennifer Green; Elbert Huang; Diana Isaacs; Scott Kahan; Jose Leon; Sarah K Lyons; Anne L Peters; Priya Prahalad; Jane E B Reusch; Deborah Young-Hyman
Journal:  Diabetes Care       Date:  2022-01-01       Impact factor: 19.112

2.  Using an Electronic Health Record and Deficit Accumulation to Pragmatically Identify Candidates for Optimal Prescribing in Patients With Type 2 Diabetes.

Authors:  Kathryn E Callahan; Kristin M Lenoir; Chinenye O Usoh; Jeff D Williamson; LaShanda Y Brown; Adam W Moses; Molly Hinely; Zeev Neuwirth; Nicholas M Pajewski
Journal:  Diabetes Spectr       Date:  2022-03-21

3.  Challenges and Strategies for Diabetes Management in Community-Living Older Adults.

Authors:  Alan J Sinclair; Ahmed H Abdelhafiz
Journal:  Diabetes Spectr       Date:  2020-08

4.  Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes.

Authors:  Zoltán Taybani; Balázs Bótyik; Mónika Katkó; András Gyimesi; Tamás Várkonyi
Journal:  Diabetes Ther       Date:  2019-07-25       Impact factor: 2.945

5.  Preventable adverse drug events: Descriptive epidemiology.

Authors:  Stephanie A Woo; Amber Cragg; Maeve E Wickham; Diane Villanyi; Frank Scheuermeyer; Jeffrey P Hau; Corinne M Hohl
Journal:  Br J Clin Pharmacol       Date:  2020-01-10       Impact factor: 4.335

6.  Older people's attitudes towards deprescribing cardiometabolic medication.

Authors:  Stijn Crutzen; Jamila Abou; Sanne E Smits; Gert Baas; Jacqueline G Hugtenburg; Mette Heringa; Petra Denig; Katja Taxis
Journal:  BMC Geriatr       Date:  2021-06-16       Impact factor: 3.921

Review 7.  Rates, determinants and success of implementing deprescribing in people with type 2 diabetes: A scoping review.

Authors:  M P Oktora; K P Kerr; E Hak; P Denig
Journal:  Diabet Med       Date:  2020-10-02       Impact factor: 4.359

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.